View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest, Kútvölgyi út 4., 1125
  • | 2 Egyesített Szent István és Szent László Kórház-Rendelőintézet, Budapest
  • | 3 Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen
Open access

Absztrakt

A myeloma multiplex kezelése az elmúlt évtizedben óriásit változott. Mind a kemoterápiás protokollok, mind a szupportív kezelés nagy fejlődésen ment át, amióta a legutóbbi magyar ajánlás megjelent. A betegek egyre nagyobb része ér el tartós választ, és mind többük számára van talán esély a gyógyulásra is. Az összefoglaló célja, hogy az utóbbi évek eredményeit is beépítve, az érvényes nemzetközi ajánlásokat a magyar viszonyok sajátosságaihoz adaptálva segítse a betegek leghatékonyabb kezelését. Orv. Hetil., 2016, 157(4), 123–137.

  • 1

    Engelhardt, M., Terpos, E., Kleber, M., et al.: European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica, 2014, 99(2), 232–242.

  • 2

    Radványi, G., Mikala, G., Masszi, T., et al.: Diagnosis and treatment of multiple myeloma (MM). In: Lehoczky, D. (ed.): Current treatment of hematologic diseases. Treatment guideline of the Hungarian Professional Board of Transfusion and Hematology. [A myeloma multiplex (MM) diagnózisa és kezelése. In: Lehoczky, D. (szerk.): Hematológiai betegségek korszerű kezelése. A Magyar Transzfuziológiai és Hematológiai Szakmai Kollégium és a Tudományos Társaság kezelési irányelvei.] Zafír Press, Budapest, 2014. [Hungarian]

  • 3

    Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., et al.: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol., 2014, 15(12), e538–e548.

  • 4

    Kyle, R. A., Gertz, M. A., Witzig, T. E., et al.: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc., 2003, 78(1), 21–33.

  • 5

    Fonseca, R., Bergsagel, P. L., Drach J., et al.: International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia, 2009, 23(12), 2210–2221.

  • 6

    Klein, B., Seckinger, A., Moehler, T., et al.: Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks and the bone marrow microenvironment. Recent Results Cancer Res., 2011, 183, 39–86.

  • 7

    Bergsagel, P. L., Kuehl, W. M., Zhan, F., et al.: Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood, 2005, 106(1), 296–303.

  • 8

    Chapman, M. A., Lawrence, M. S., Keats, J. J., et al.: Initial genome sequencing and analysis of multiple myeloma. Nature, 2011, 471(7339), 467–472.

  • 9

    Lohr, J. G., Stojanov, P., Carter, S. L., et al.: Widespread genomic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell, 2014, 25(1), 91–101.

  • 10

    Egan, J. B., Shi, C. X., Tembe, W., et al.: Whole genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution and clonal tides. Blood, 2012, 120(5), 1060–1066.

  • 11

    Broyl, A., Hose, D., Lokhorst, H., et al.: Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood, 2010, 116(14), 2543–2553.

  • 12

    Walker, B. A., Boyle, E. M., Wardell, C. P., et al.: Mutational spectrum, copy number changes, and outcome: Results of a sequencing study of patients with newly diagnosed myeloma. J. Clin. Oncol., 2015, 33(33), 3911–3920.

  • 13

    Lionetti, M., Barbieri, M., Todoerti K., et al.: Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication of MEK-ERK pathway activation. Oncotarget, 2015, 6(27), 24205–24217.

  • 14

    Seckinger, A., Hose, D.: Dissecting the clonal architecture of multiple myeloma. 20th Congress of the European Hematology Association, Vienna, Austria. Haematologica, 2015, 9, 173–179.

  • 15

    Walker, B. A., Wardell, C. P., Melchor, L., et al.: Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia, 2014, 28(2), 384–390.

  • 16

    Keats, J. J., Chesi, M., Egan, J. B., et al.: Clonal competition with alternating dominance in multiple myeloma. Blood, 2012, 120(5), 1067–1076.

  • 17

    Melchor, L., Brioli, A., Wardell, C. P., et al.: Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia, 2014, 28(8), 1705–1715.

  • 18

    Morgan, G. J., Walker, B. A., Davies, F. E., et al.: The genetic architecture of multiple myeloma. Nat. Rev. Cancer, 2012, 12(5), 335–348.

  • 19

    Bianchi, G., Ghobrial, I. M.: Biological and clinical implications of clonal heterogeneity and clonal evolution in multiple myeloma. Curr. Cancer Ther. Rev., 2014, 10(2), 70–79.

  • 20

    Kyle, R. A., Rajkumar, S. V.: Multiple myeloma. N. Engl. J. Med., 2004, 351(18), 1860–1873.

  • 21

    Raja, K. R., Kovarova, L., Hajek, R.: Review of phenotypic markers used in flow cytometric analysis of MGUS and MM and applicability of flow cytometry in other plasma cell disorders. Br. J. Haematol., 2010, 149(3), 334–351.

  • 22

    Fonseca, R., Monge, J., Dimopoulos, M. A.: Staging and prognostication of multiple myeloma. Expert Rev. Hematol., 2014, 7(1), 21–31.

  • 23

    Jenner, E.: Serum free light chains in clinical laboratory diagnostics. Clin. Chim. Acta, 2014, 427, 15–20.

  • 24

    Palumbo, A., Avet-Loiseau, H., Oliva, S., et al.: Revised International Staging System for multiple myeloma: A report from International Myeloma Working Group. J. Clin. Oncol., 2015, 33(26), 2863–2869.

  • 25

    Derlin, T., Bannas, P.: Imaging of multiple myeloma: current concepts. World J. Orthop., 2014, 5(3), 272–282.

  • 26

    Gleeson, T. G., Moriarty, J., Shortt, C. P., et al.: Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions and correlation of disease distribution with whole body MRI (WBMRI). Skeletal Radiol., 2009, 38(3), 225–236.

  • 27

    Hanrahan, C. J., Christensen, C. R., Crim, J. R.: Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT. Radiographics, 2010, 30(1), 127–142.

  • 28

    Mikala, G., Jákó, J., Vályi-Nagy, I.: The role of thalidomide in the treatment of multiple myeloma. [A thalidomid szerepe a myeloma multiplex gyógykezelésében.] Orv. Hetil., 2001, 142(33), 1789–1798. [Hungarian]

  • 29

    Mikala, G., Jákó, J., Vályi-Nagy, I.: Proteasome inhibition: a new therapeutic approach for the treatment of multiple myeloma. [Proteaszómagátlás: új terápiás lehetőség myeloma multiplex kezelésére.] Orv. Hetil., 2004, 145(2), 67–74. [Hungarian]

  • 30

    Varga, G., Mikala, G., Andrikovics, H., et al.:NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first linetreated multiple myeloma. Br. J. Haematol., 2015, 168(5), 679–688.

  • 31

    Moreau, P., Pylypenko, H., Grosicki, S., et al.: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol., 2011, 12(5), 431–440.

  • 32

    Mikala, G., Bátai, Á., Ceglédi, A., et al.: Our experience with bortezomib-based therapy of multiple myeloma based on the first 60 patients. [A myeloma multiplex bortezomibalapú kezelése – Hazai tapasztalatok az első 60 beteg adatainak tükrében.] LAM, 2007, 17(1), 26–34. [Hungarian]

  • 33

    Zimmerman, T. M., Griffith, K. A., Jasielec, J.: Phase II MMRC trial of extended treatment with carfilzomib, lenalidomide, and dexamethasone plus autologous stem cell transplantation in newly diagnosed multiple myeloma. J. Clin. Oncol., 2015, 33(Suppl.), abstr. 8510.

  • 34

    Lokhorst, H. M., Laubach, J., Nahi, H.: Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM). J. Clin. Oncol., 2014, 32(Suppl.), abstr. 8513.

  • 35

    Lonial, S., Dimopoulos, M. A., Palumbo, A.: ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide/dexamethasone with/without elotuzumab in patients with relapsed/refractory multiple myeloma. J. Clin. Oncol., 2015, 33(Suppl.), abstr. 8508.

  • 36

    Gorgun, G., Samur, M. K., Cowens, K. B., et al.: Lenalidomide enhances immune checkpoint blockade induced immune response in multiple myeloma. Clin. Cancer Res., 2015, 21(20), 4607–4618.

  • 37

    Rosiñol, L., Oriol, A., Teruel, A. I.: Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood, 2012, 120(8), 1589–1596.

  • 38

    Reeder, C. B., Reece, D. E., Kukreti, V., et al.: Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia, 2009, 23(7), 1337–1341.

  • 39

    Sonneveld, P., Schmidt-Wolf, I. G., van der Holt, B., et al.: Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J. Clin. Oncol., 2012, 30(24), 2946–2955.

  • 40

    Leiba, M., Kedmi, M., Duek, A., et al.: Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. Br. J. Haematol., 2014, 166(5), 702–710.

  • 41

    Painuly, U., Kumar, S.: Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. Clin. Med. Insights Oncol., 2013, 7, 53–73.

  • 42

    Palumbo, A., Bringhen, S., Mateos, M. V., et al.: Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood, 2015, 125(13), 2068–2074.

  • 43

    Rajkumar, S. V., Jacobus, S., Callander N. S., et al.: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol., 2010, 11(1), 29–37.

  • 44

    Richardson, P. G., Weller, E., Lonial, S., et al.: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood, 2010, 116(5), 679–686.

  • 45

    San Miguel, J. F., Schlag, R., Khuageva, N. K., et al.: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med., 2008, 359(9), 906–917.

  • 46

    Morgan, G. J., Davies, F. E., Gregory, W. M., et al.: Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin. Cancer Res., 2013, 19(21), 6030–6038.

  • 47

    Facon, T., Mary, J. Y., Hulin, C., et al.: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet, 2007, 370(9594), 1209–1218.

  • 48

    Grey-Davies, E., Bosworth, J. L., Boyd, K. D., et al.: Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. Br. J. Haematol., 2012, 156(4), 552–555.

  • 49

    Lentzsch, S., O’Sullivan, A., Kennedy, R. C.: Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood, 2012, 119(20), 4608–4613.

  • 50

    Bringhen, S., Petrucci, M. T., Larocca, A., et al.: Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood, 2014, 124(1), 63–69.

  • 51

    Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., et al.: Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med., 2015, 372(2), 142–152.

  • 52

    Kumar, S. K., Berdeja, J. G., Niesvizky, R., et al.: Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol., 2014, 15(13), 1503–1512.

  • 53

    Richardson, P. G., Siegel, D. S., Vij, R., et al.: Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood, 2014, 123(12), 1826–1832.

  • 54

    Barlogie, B., Velasquez, W. S., Alexanian, R., et al.: Etoposide, dexamethasone, cytarabine and cisplatin in vincristine, doxorubicin and dexamethasone-refractory myeloma. J. Clin. Oncol., 1989, 7(10), 1514–1517.

  • 55

    Barlogie, B., Anaissie, E., van Rhee, F., et al.: Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br. J. Haematol., 2007, 138(2), 176–185.

  • 56

    Pozzi, S., Marcheselli, L., Bari, A., et al.: Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br. J. Haematol., 2013, 163(1), 40–46.

  • 57

    Mikhael, J. R., Dingli, D., Roy, V., et al.: Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin. Proc., 2013, 88(4), 360–376.

  • 58

    Varga, G., Reményi, P., Mikala, G., et al.: Single center experience with early versus late autologous stem cell transplantation in multiple myeloma. Haematologica, 2015, 100, 652.

  • 59

    Masszi, T.: Hemopoietic stem cell transplantation in Hungary: activity and indications. [Hemopoietikus őssejt-transzplantáció Magyarországon: aktivitás és indikációk.] Transzfúzió, 2000, 33(2), 67–71. [Hungarian]

  • 60

    Cook, G., Williams, C., Brown, J. M., et al.: High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol., 2014, 15(8), 874–885.

  • 61

    Vesole, D. H., Zhang, L., Flomenberg, N., et al.: A phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97. Biol. Blood Marrow Transplant., 2009, 15(1), 83–91.

  • 62

    Rajkumar, S. V., Harousseau, J. L., Durie, B., et al.: Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 2011, 117(18), 4691–4695.

  • 63

    Chen, C. I., Masih-Khan, E., Jiang, H., et al.: Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br. J. Haematol., 2013, 162(4), 483–488.

  • 64

    Ashley, C., Dunleavey, A. (eds.): The renal drug handbook. Radcliffe Publishing, London, 2014.

  • 65

    Sinkó, J., Cser, V., Konkoly Thege, M., et al.: Gram-negative bacteremia in neutropenic patients with hematologic disorders. Experiences with prophylactic use of fluoroquinolones. [Gram-negatív bacteriaemia neutropeniás hematológiai betegekben. Tapasztalatok fluorokinolonprofilaxis alkalmazása kapcsán.] Orv. Hetil., 2011, 152(27), 1063–1067. [Hungarian]

  • 66

    Snowden, J. A., Ahmedzai, S. H., Ashcroft, J., et al.: Guidelines for supportive care in multiple myeloma 2011. Br. J. Haematol., 2011, 154(1), 76–103.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 383 270 23
PDF Downloads 704 592 21